{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:28:31Z","timestamp":1793996911430,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","award":["92541640"],"award-info":[{"award-number":["92541640"]}],"id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand up to Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-CT1017"],"award-info":[{"award-number":["SU2C-AACR-CT1017"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejca.2025.115688","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:53:11Z","timestamp":1754441591000},"page":"115688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-8692","authenticated-orcid":false,"given":"Tina J.","family":"Hieken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zahrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Flotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana S.","family":"Dronca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-554X","authenticated-orcid":false,"given":"Evidio","family":"Domingo-Musibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0709-1155","authenticated-orcid":false,"given":"Garth D.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7820-6138","authenticated-orcid":false,"given":"Carrie A.","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Kottschade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7488-4767","authenticated-orcid":false,"given":"Heather N.","family":"Montane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0863-8258","authenticated-orcid":false,"given":"Mara A.","family":"Piltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5376-4835","authenticated-orcid":false,"given":"Ruqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"McWilliams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-1072","authenticated-orcid":false,"given":"James W.","family":"Jakub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Khariwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9114-8945","authenticated-orcid":false,"given":"Arkadiusz Z.","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-443X","authenticated-orcid":false,"given":"Jeffrey E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3950-3305","authenticated-orcid":false,"given":"Anastasios","family":"Dimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-1721","authenticated-orcid":false,"given":"Kendall K.","family":"Tasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-4219","authenticated-orcid":false,"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejca.2025.115688_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-Only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2025.115688_bib2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"7710","key":"10.1016\/j.ejca.2025.115688_bib3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in t cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejca.2025.115688_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2376782","article-title":"Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes","volume":"13","author":"Cadiou","year":"2024","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ejca.2025.115688_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses t cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat Immunol"},{"issue":"42","key":"10.1016\/j.ejca.2025.115688_bib6","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.ejca.2025.115688_bib7","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s43018-024-00870-6","article-title":"TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor t cells by facilitating co-stimulation","volume":"5","author":"Nutsch","year":"2024","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115688_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaad.2019.03.012","article-title":"Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes","volume":"81","author":"Lee","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115688_bib9","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/cam4.2167","article-title":"Expression of immune checkpoint receptors indoleamine 2,3-dioxygenase and t cell ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma","volume":"8","author":"Stalhammar","year":"2019","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.ejca.2025.115688_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/CJI.0000000000000429","article-title":"CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA methylation is associated with BAP1 -Aberrancy, transcriptional activity, and overall survival in uveal melanoma","volume":"45","author":"de Vos","year":"2022","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.ejca.2025.115688_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13148-022-01270-2","article-title":"DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy","volume":"14","author":"Niebel","year":"2022","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.ejca.2025.115688_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155468","article-title":"Expression of immune checkpoint molecules TIGIT and TIM-3 by tumor-infiltrating lymphocytes predicts poor outcome in sinonasal mucosal melanoma","volume":"260","author":"Ledderose","year":"2024","journal-title":"Pathol Res Pract"},{"issue":"6","key":"10.1016\/j.ejca.2025.115688_bib13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study","volume":"23","author":"Cho","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115688_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.23.01363","article-title":"SKYSCRAPER-02: tiragolumab in combination with atezolizumab plus chemotherapy in untreated Extensive-Stage Small-Cell lung cancer","volume":"42","author":"Rudin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115688_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1136\/ijgc-2024-005588","article-title":"A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)","volume":"34","author":"Salani","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.115688_bib16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1038\/s41467-024-45798-8","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable stage III melanoma: the phase II NeoACTIVATE trial","volume":"15","author":"Hieken","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.ejca.2025.115688_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011706","article-title":"Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial","volume":"13","author":"Block","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.115688_bib18","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"issue":"7934","key":"10.1016\/j.ejca.2025.115688_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"S2","key":"10.1016\/j.ejca.2025.115688_bib20","doi-asserted-by":"crossref","first-page":"S1232","DOI":"10.1016\/j.annonc.2024.08.2282","article-title":"LBA41 Long-term survival with neoadjuvant therapy in melanoma: updated pooled analysis from the international neoadjuvant melanoma consortium (INMC)","volume":"35","author":"Long","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115688_bib21","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1245\/s10434-021-11236-y","article-title":"Neoadjuvant systemic therapy (NAST) in patients with melanoma: surgical considerations by the international neoadjuvant melanoma consortium (INMC","volume":"29","author":"van Akkooi","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115688_bib22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-024-03411-x","article-title":"Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1\/2 trial","volume":"31","author":"Dummer","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.ejca.2025.115688_bib23","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"International neoadjuvant melanoma consortium. Neoadjuvant systemic therapy in melanoma: recommendations of the international neoadjuvant melanoma consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925004708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925004708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T09:50:18Z","timestamp":1772877018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925004708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"alternative-id":["S0959804925004708"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115688","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115688"}}